Regeneron Pharmaceuticals Inc (REGN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Regeneron Pharmaceuticals rose $5.39 (1.8%) to $298.98 on light volume. Throughout the day, 804,778 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,183,100 shares. The stock ranged in a price between $289.73-$299.86 after having opened the day at $291.73 as compared to the previous trading day's close of $293.59. Other companies within the Health Care sector that increased today were: Medical Action Industries ( MDCI), up 11.9%, Fibrocell Science ( FCSC), up 10.8%, Karyopharm Therapeutics ( KPTI), up 9.3% and Synthetic Biologics ( SYN), up 9.2%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $28.7 billion and is part of the drugs industry. The company has a P/E ratio of 87.4, above the S&P 500 P/E ratio of 17.7. Shares are up 6.7% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share.

On the negative front, Actinium Pharmaceuticals ( ATNM), down 8.0%, Biota Pharmaceuticals ( BOTA), down 7.5%, Star Scientific ( STSI), down 6.8% and Inovio Pharmaceuticals ( INO), down 6.2% , were all laggards within the health care sector with AstraZeneca ( AZN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%